IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis : Episode 9

Opinion

Video

February 11, 2025

Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

Panelists discuss the maintenance of treatment efficacy in the lebrikizumab clinical trial, highlighting data on sustained improvement in atopic dermatitis symptoms over time and the long-term effectiveness of the treatment.

EP: 1.Heterogenous Presentation Of Atopic Dermatitis

EP: 2.Use of Biopsy and Diagnosing New-Onset AD

EP: 3.Treatment Options in Atopic Dermatitis

EP: 4.Improvement in Standard of Care in Atopic Dermatitis

EP: 5.Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

EP: 6.Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP: 7.IL-13–Targeting Agents in Atopic dermatitis

EP: 8.Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

EP: 9.Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

EP: 10.Switching or Staying Within the Treatment Class

Video content above is prompted by the following:

Can you discuss maintenance of treatment efficacy in the lebrikizumab clinical trial?

Related Videos

3 experts are featured in this series.

3 experts are featured in this series.

Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD

Sobia Laique, MD | Credit: Cleveland Clinic

Sobia Laique, MD | Credit: Cleveland Clinic

What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.